Medtronic plc (MDT) — Fundamental Analysis

Medtronic is a large, mature medical device company that generates consistent profits and strong cash flows, but grows slowly. Over the past several years, revenue has expanded at a mid-single-digit pace — roughly 5% annually over the last three years and under 4% over five years — while operating and net margins have held broadly steady in the high-teens and low-to-mid-teens, respectively. The balance sheet is conservatively managed, with the company carrying very little net debt relative to equity in most recent years and maintaining a healthy current ratio well above 1. Capital spending has risen in dollar terms but remains a modest share of revenue. In short, Medtronic looks like a financially sound, slow-growth healthcare incumbent: reliable, but not a high-octane growth story.

Snapshot & Big Picture

Medtronic (NYSE: MDT) is one of the world's largest medical technology companies, with products spanning cardiac rhythm management, spine, diabetes, surgical robotics, and more. Its fiscal year ends in late April. The most recent full fiscal year (ending April 25, 2025) reported revenue of $33.5 billion, while the just-completed fiscal year ending April 24, 2026 pushed that to $36.4 billion — the highest in the data set shown here. EBITDA has tracked broadly in line with revenue growth, coming in at $9.4 billion for fiscal 2026. The company has navigated a period of post-pandemic normalization and product portfolio investment while keeping profitability metrics relatively stable.

Latest Quarter Snapshot

The most recent quarterly data — the quarter ending April 24, 2026, which is the final quarter of fiscal year 2026 and therefore more current than the annual figures — gives a real-time read on where Medtronic stands today. Revenue for the quarter came in at $9.81 billion, with an operating margin of 19.1% and a net margin of 12.7%. Notably, gross margin for this quarter was reported at 38.1% (annual gross margin figures were not available in the 10-K filings for most years, with the exception of fiscal 2017 and 2018). CapEx for the quarter was $488 million, representing 5.0% of quarterly revenue. The current ratio held at 2.13, reflecting solid short-term liquidity. The quarterly debt-to-equity ratio of 0.48 is higher than the annual figure of 0.04 reported for full-year fiscal 2026, which may reflect timing differences in how liabilities are classified at different reporting periods.

Profitability

Medtronic's profitability has been broadly resilient, though not without fluctuation. Operating margins peaked around 22% in fiscal 2018 before compressing meaningfully during the pandemic-affected fiscal 2020 and 2021 periods, where they dipped to the mid-to-high teens. Since fiscal 2022, operating margins have stabilized in the 16–18% range. Net margins tell a similar story: they ran above 15% in fiscal 2019 and 2022, dipped to around 11–12% in fiscal 2023 and 2024, and recovered modestly to ~13–14% in fiscal 2025 and 2026. The most recent two fiscal years show a consistent operating margin right around 17.8%, suggesting the business has found a steadier operating baseline after the turbulence of the early 2020s. EBITDA recovered from a trough of $7.2 billion in fiscal 2021 to $9.4 billion in fiscal 2026 — a positive trend, though the absolute level is only modestly above where it was in fiscal 2018 and 2019, underscoring the slow-growth nature of the business.

Financial Health

Medtronic's balance sheet is in good shape. The current ratio has consistently stayed above 1.7 across the entire period shown, and was 2.13 at the close of fiscal 2026 — indicating that short-term assets comfortably cover short-term liabilities. Debt-to-equity, as reported in the annual filings, has declined substantially from levels of 0.51–0.67 seen in fiscal 2017–2019 to near-zero in fiscal 2021 and 2023. The spike back to 0.07 in fiscal 2022 and 2025 and the quarterly reading of 0.48 warrant monitoring, but overall the company does not appear to be in a leveraged stress situation.

On capital expenditures: Medtronic has been spending more in absolute dollar terms each year, rising from $1.07 billion in fiscal 2018 to $1.90 billion in fiscal 2026. However, as a share of revenue, CapEx has been relatively contained — ranging from about 3.6% to 5.5% of revenue across the full period. The trend in CapEx-to-revenue has drifted modestly upward over the past few years (from around 4.3% in fiscal 2022 to 5.2% in fiscal 2026), suggesting a slight increase in capital intensity as the company invests in new platforms and manufacturing capabilities, but this remains a moderate reinvestment burden for a company of this size and profitability.

Growth

Medtronic's revenue growth has been modest, consistent with a large, established medical device company operating in relatively mature product markets. The three-year CAGR is somewhat better than the five-year figure, reflecting a bounce-back from pandemic-era weakness that weighed on the fiscal 2021 base. The 10-year CAGR is not available in this data set — the SEC filing history provided does not extend back far enough to anchor a full ten-year calculation from today's fiscal year end.

A 5-year CAGR of 3.8% and a 3-year CAGR of 5.2% paint a picture of a company that is growing, but slowly — roughly in line with or slightly above broader healthcare end-market growth rates. The improvement in the shorter window is encouraging and may reflect new product launches and procedure volume recovery post-pandemic, but investors seeking high revenue growth rates are unlikely to find that here.

Source Filings

• 10-K filed June 18, 2026 (Fiscal Year ending April 24, 2026)
• 10-Q filed February 24, 2026 (Quarter ending January 23, 2026)